Hydroxychloroquine/Ribavirin

羟氯喹/利巴韦林

Report date: 2022/12/07 17:15:17

Base Information

Drug NameHydroxychloroquine/Ribavirin

Drug Alias NameHydroxychloroquine+Ribavirin利巴韦林+羟氯喹Ribavirin+Hydroxychloroquine利巴韦林/羟氯喹羟氯喹+利巴韦林 +[7]

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues

Mechanisms of ActionInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitorsBacterial DNA-directed RNA polymerase inhibitorsmRNA guanylyltransferase inhibitors

TargetsInosine-5'-monophosphate dehydrogenase (IMPDH)Bacterial DNA-directed RNA polymerasemRNA guanylyltransferase

Therapy Area/IndicationsHepatitis C

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsYes Ribavirin Hydroxychloroquine sulfate

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPanmed Genoscience Pharma Biolinerx Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBiolinerx Ltd Panmed Genoscience Pharma

Active IndicationsN/A

Inactive IndicationsHepatitis C

Other Information

ATC CodeN/A